First Trust Advisors LP Boosts Stake in LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP boosted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 52.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 612,028 shares of the medical instruments supplier’s stock after purchasing an additional 211,280 shares during the period. First Trust Advisors LP’s holdings in LeMaitre Vascular were worth $50,829,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of LMAT. Parkside Financial Bank & Trust raised its stake in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the period. Geneos Wealth Management Inc. raised its stake in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the period. EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular during the second quarter valued at approximately $47,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of LeMaitre Vascular in the first quarter worth approximately $50,000. Finally, US Bancorp DE boosted its position in shares of LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 368 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $82.93 on Tuesday. The firm has a market cap of $1.88 billion, a PE ratio of 35.75, a PEG ratio of 2.09 and a beta of 0.68. The stock has a 50 day moving average of $86.83 and a 200 day moving average of $87.14. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The business had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Barrington Research reissued an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of LeMaitre Vascular in a research note on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.